Discontinuation of antipsychotic medication-time to rethink trial design

Helene Speyer; Marieke Begemann; Nikolai Albert; Amber Weller; Merete Nordentoft; Wim Veling; Iris E Sommer; Kelly Allott; Eóin Killackey

doi:10.1016/S2215-0366(20)30340-0

Discontinuation of antipsychotic medication-time to rethink trial design

Helene Speyer^*, Marieke Begemann, Nikolai Albert, Amber Weller, Merete Nordentoft, Wim Veling, Iris E Sommer, Kelly Allott, Eóin Killackey

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Original language	English
Pages (from-to)	841-842
Number of pages	2
Journal	The Lancet. Psychiatry
Volume	7
Issue number	10
DOIs	https://doi.org/10.1016/S2215-0366(20)30340-0
Publication status	Published - Oct-2020

Keywords

Antipsychotic Agents/therapeutic use
Humans
Medication Adherence
Patient Dropouts
Patient Selection
Psychotic Disorders/drug therapy
Randomized Controlled Trials as Topic
Recurrence
Research Design

Access to Document

10.1016/S2215-0366(20)30340-0

Embargoed Document

Discontinuation of antipsychotic medication—time to rethink trial design
Final publisher's version, 1.43 MB
Request copy

Cite this

@article{8d5f8c1105a041caaffb533f8d080b8a,

title = "Discontinuation of antipsychotic medication-time to rethink trial design",

keywords = "Antipsychotic Agents/therapeutic use, Humans, Medication Adherence, Patient Dropouts, Patient Selection, Psychotic Disorders/drug therapy, Randomized Controlled Trials as Topic, Recurrence, Research Design",

author = "Helene Speyer and Marieke Begemann and Nikolai Albert and Amber Weller and Merete Nordentoft and Wim Veling and Sommer, {Iris E} and Kelly Allott and E{\'o}in Killackey",

year = "2020",

month = oct,

doi = "10.1016/S2215-0366(20)30340-0",

language = "English",

volume = "7",

pages = "841--842",

journal = "The Lancet. Psychiatry",

issn = "2215-0366",

publisher = "ELSEVIER SCI LTD",

number = "10",

}

Discontinuation of antipsychotic medication-time to rethink trial design. / Speyer, Helene; Begemann, Marieke; Albert, Nikolai; Weller, Amber; Nordentoft, Merete; Veling, Wim ; Sommer, Iris E; Allott, Kelly; Killackey, Eóin.

In: The Lancet. Psychiatry, Vol. 7, No. 10, 10.2020, p. 841-842.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Discontinuation of antipsychotic medication-time to rethink trial design

AU - Speyer, Helene

AU - Begemann, Marieke

AU - Albert, Nikolai

AU - Weller, Amber

AU - Nordentoft, Merete

AU - Veling, Wim

AU - Sommer, Iris E

AU - Allott, Kelly

AU - Killackey, Eóin

PY - 2020/10

Y1 - 2020/10

KW - Antipsychotic Agents/therapeutic use

KW - Humans

KW - Medication Adherence

KW - Patient Dropouts

KW - Patient Selection

KW - Psychotic Disorders/drug therapy

KW - Randomized Controlled Trials as Topic

KW - Recurrence

KW - Research Design

U2 - 10.1016/S2215-0366(20)30340-0

DO - 10.1016/S2215-0366(20)30340-0

M3 - Comment/Letter to the editor

C2 - 32949515

VL - 7

SP - 841

EP - 842

JO - The Lancet. Psychiatry

JF - The Lancet. Psychiatry

SN - 2215-0366

IS - 10

ER -